Agenda
Friday, February 21, 2025
| 7 - 7:55 a.m. | Registration and Breakfast |
| 7:55 - 8 a.m. | Opening Remarks Daruka Mahadevan, MD, PhD, Mays Cancer Center at UT Health San Antonio |
Special SessionBiopharma perspectives on anti-cancer therapeutic development | |
| 8 - 8:30 a.m. | Developing anti-cancer therapeutics that activate macrophage-mediated phagocytosis Ming Wang, PhD, Phanes Therapeutics, San Diego, California |
| 8:30 - 9 a.m. | Break and Exhibition |
Session 1Moderator: Daruka Mahadevan, MD, PhD, Mays Cancer Center at UT Health San Antonio | |
| 9 - 9:30 a.m. | Science-driven early phase clinical trials to dissect molecular mechanisms of drug sensitivity and resistance Lillian Siu, MD, Princess Margaret Cancer Centre, Toronto, Canada |
| 9:30 -10 a.m. | Novel ADCs targeting the immune checkpoint Daruka Mahadevan, MD, PhD, Mays Cancer Center at UT Health San Antonio |
| 10 -10:30 a.m. | Develop T cell receptor (TCR)-T cell therapy that targets HLA-class I and class II natural epitope Lei Zheng, MD, PhD, Mays Cancer Center at UT Health San Antonio |
| 10:30 - 10:40 a.m. | Break, Networking, and Exhibition |
| 10:40 - 11:20 a.m. | Advances in lung cancer Hatim Husain, MD, University of California at San Diego Moores Cancer Center |
| 11:20 - 11:50 a.m. | Identifying therapeutic targets by computational analysis of clinical molecular data Ritu Pandey, PhD, The University of Arizona |
| 11:50 a.m. - 12:10 p.m. | Q&A |
| 12:10 - 1:20 p.m. | Lunch, Networking, and Exhibits |
Session 2 | |
| 1:20 - 1:50 p.m. | Evolving cellular therapy landscape in hematologic malignancies and solid tumor Muhammad Bilal Abid, MD, MS, UT Health Houston |
| 1:50 - 2:20 p.m. | The advances in drug development/treatment in Mantle Cell Lymphoma Preetesh Jain, MD, MD Anderson Cancer Center, Houston, Texas |
| 2:20 - 2:50 p.m. | Moving the needle in Acute Myeloid Leukemia Ronan Swords, MD, Oregon Health & Science University, Portland, Oregon |
| 2:50 - 3:10 p.m. | Break, Networking and Exhibition |
| 3:10 - 3:40 p.m. | Improving DLBCL outcomes: A perfect marriage of optimizing trial design and the use of surrogate endpoints Adolfo Enrique Diaz, MD, Mays Cancer Center at UT Health San Antonio |
| 3:40 - 4:10 p.m. | Bispecific T-cell engaging antibodies: a new frontier in immunotherapy Matthew Butler, MD, Mays Cancer Center at UT Health San Antonio |
| 4:10 - 4:20 p.m. | Q&A |
| 4:20 p.m. | Day 1 Adjourns |
Saturday, February 22, 2025
| 7 - 7:55 a.m. | Registration and Breakfast |
Session 3Moderator: Daruka Mahadevan, MD, PhD, Mays Cancer Center at UT Health San Antonio | |
| 8 - 8:30 a.m. | Identifying Vulnerabilities in Cancer Hans-Guido Wendel, MD, Memorial Sloan Kettering Cancer Center, New York City |
| 8:30 - 9 a.m. | Targeting MTAP loss: A synthetic lethality opportunity hidden in plain sight Jordi Rodon, MD, PhD, MD Anderson Cancer Center, Houston, Texas |
| 9 - 9:10 a.m | Break, Networking and Exhibit |
| 9:10 - 9:40 a.m. | Polyploid Giant Cancer Cells: Toward unified understanding of Embryogenesis Tumorigenesis, and Therapeutic Resistance Jinsong Liu, MD, PhD, MD Anderson Cancer Center, Houston, Texas |
| 9:40 - 10:10 a.m. | Targeting DNA damage repair in triple negative breast cancer Eloise Dray, PhD, Mays Cancer Center at UT Health San Antonio |
| 10:10 - 10:20 a.m. | Q&A |
Session 4Moderator: John Sarantopoulos, MD, Mays Cancer Center at UT Health San Antonio | |
| 10:20 - 10:50 a.m. | Recent updates in metastatic melanoma Jane Mattei, MD, PhD, Mays Cancer Center at UT Health San Antonio |
| 10:50 - 11:20 a.m. | Future directions in breast cancer Murali Beeram, MD, START Center for Cancer Care, San Antonio, Texas |
| 11:20 - 11:50 a.m. | Immunotherapy for head and neck squamous cell carcinoma: Present and future approaches and challenges Devi Meyyappan, MD, Mays Cancer Center at UT Health San Antonio |
| 11:50 a.m. - 12:00 p.m. | Q&A |
| 12:00 - 1:10 p.m. | Lunch |
Session 5Moderator: John Sarantopoulos, MD, Mays Cancer Center at UT Health San Antonio | |
| 1:10 - 1:25 p.m. | First in human phase 1 study of DT2216, a selective BCS-xL degrader, in patients in relapsed/refractory solid malignancies Jay Parekh, MD, Mays Cancer Center at UT Health San Antonio |
| 1:25 - 1:40 p.m. | Enhancing Oncology Care: Data and insights from the ACS - Agilix nutrition program at Mays Cancer Center Sheniell Granato, RN, Mays Cancer Center at UT Health San Antonio |
| 1:40 - 1:45 p.m. | Q&A |
| 1:45 - 2 p.m. | Awards and Closing Remarks Daruka Mahadevan, MD, PhD, Mays Cancer Center at UT Health San Antonio, and John Sarantopoulos, MD, Mays Cancer Center at UT Health San Antonio |
| 2 p.m. | Symposium Concludes |
Mays Cancer Center
7979 Wurzbach Road
San Antonio, Texas
P: (210) 450 1550
Email: panao@uthscsa.edu